Galapagos CEO tightens strategic focus in pursuit of key assets
For many observers, Galapagos is in an enviable position. The biotech has a balance sheet of €3bn to call upon …
Post
-
-
“Reckless and harmful”: experts weigh in on CDC’s autism-vaccine link stance
The Centers for Disease Control and Prevention (CDC) has updated its website to state that there could be a link …
-
Early planning, outsourcing and digitalisation to break down CGT CMC barriers
Since their inception, cell and gene therapies (CGTs) have shown great promise in treating a plethora of challenging diseases. Despite their …
-
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
US-based Aspen Neuroscience has closed a Series C funding round, raising $115m to further the clinical development of its lead …
-
Alvotech and Advanz announce EC approval for Gobivaz biosimilar
Alvotech and Advanz Pharma have announced the European Commission’s (EC) marketing authorisations for Gobivaz, a biosimilar to Simponi (golimumab), across …
-
CPHI 2025: linker innovation paves the way for a wave of new ADCs
Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to their therapeutic payloads, are opening the door …
-
Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership
Merck KGaA has signed a drug discovery partnership with Valo Health, becoming the latest big pharma to enlist the services …
-
Moderna to onshore drug product manufacturing to Massachusetts
Moderna is to expand its US manufacturing capabilities with the onshoring of drug product manufacture to its existing Moderna Technology …
-
Regeneron’s Eylea franchise boosted by pair of FDA approvals
Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication to its …
-
Novartis taps North Carolina as new manufacturing hub location
Novartis has settled on North Carolina as the home for three of its newest manufacturing facilities, which will see the …
-
Pfizer and Tris reach settlement with Texas over ADHD drug allegations
Pfizer and Tris Pharma have agreed to pay $41.5m to settle allegations by Texas Attorney General Ken Paxton that they …
-
The resurgence of mesenchymal stem cell therapies
Dr. Zamilpa is the Executive Director of Biomanufacturing and Collaborative Programs at BBG Advanced Therapies, a subsidiary of BioBridge Global …
-
EC authorises Roche’s Lunsumio SC for follicular lymphoma
Roche has received conditional marketing authorisation from the European Commission (EC) for Lunsumio (mosunetuzumab) subcutaneous (SC) for adults with relapsed …
-
Alkermes prevails over Lundbeck in Avadel bidding war
Alkermes appears to have successfully hit back with a counteroffer to buy sleep disorder drugmaker Avadel, following Lundbeck’s last-minute bid …
-
Arrowhead nets first commercial win as siRNA drug garners FDA approval
Arrowhead Pharmaceuticals has hit the bullseye with its first successful commercial target, after the US Food and Drug Administration (FDA) …
